What was Nektar Therapeutics’s price range in the past 12 months?
Nektar Therapeutics lowest share price was $0.43 and its highest was $1.79 in the past 12 months.
What is Nektar Therapeutics’s market cap?
Currently, no data Available
When is Nektar Therapeutics’s upcoming earnings report date?
Nektar Therapeutics’s upcoming earnings report date is May 09, 2024 which is in 5 days.
How were Nektar Therapeutics’s earnings last quarter?
Nektar Therapeutics released its earnings results on Mar 04, 2024. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of -$0.21 by -$0.01.
Nektar Therapeutics does not currently pay dividends.
What is Nektar Therapeutics’s EPS estimate?
Nektar Therapeutics’s EPS estimate is -$0.19.
How many shares outstanding does Nektar Therapeutics have?
Nektar Therapeutics has 183,617,810 shares outstanding.
What happened to Nektar Therapeutics’s price movement after its last earnings report?
Nektar Therapeutics reported an EPS of -$0.22 in its last earnings report, missing expectations of -$0.21. Following the earnings report the stock price went down -6.519%.
Which hedge fund is a major shareholder of Nektar Therapeutics?
Among the largest hedge funds holding Nektar Therapeutics’s share is PRIMECAP Management Co. It holds Nektar Therapeutics’s shares valued at 4M.
Nektar Therapeutics is a biopharmaceutical company, which engages in applying technology platforms to develop novel drug candidates. The company focuses on the therapies for cancer, autoimmune disease, and chronic pain. It operates through the United States and Europe geographical segments. The company was founded in 1990 and is headquartered in San Francisco, CA.
Copying Jessica Fye's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +46.65% per trade.